belzupacap sarotalocan

Belzupacap sarotalocan is a first-in-class, investigational, light-actived drug conjugate composed of nanoparticles derived from human papillomavirus (HPV-NPs) conjugated to the infrared dye IR700. It is designed as a virus-like particle drug conjugate (VDC) that selectively binds to malignant cells and, upon activation with near-infrared light, induces acute tumor cell necrosis and stimulates pro-immunogenic cell death. This dual mechanism aims to both destroy cancer cells directly and elicit a durable anti-tumor immune response. The drug is being developed primarily for the treatment of uveal melanoma (including small choroidal melanoma and primary indeterminate lesions), non–muscle-invasive bladder cancer (NMIBC), and other solid tumors. Belzupacap sarotalocan has received orphan drug designation for uveal melanoma and fast track designation from the FDA[1][3][4][5][6][7][8].

Brand names

Bel-Sar

Other names

AU 011AU011AU-011bel-sarbelzupacap serotalocanlight-activated AU 011